Application of "ATTEMPTS" for drug delivery

Journal of Controlled Release

Volumn 101, Issue 1-3 SPEC. ISS., 2005, Pages 35-45

  Naik, Sarita S ^a   Liang, Jun Feng ^b   Park, Yoon Jeong ^c   Lee, Won Kyu ^a   Yang, Victor C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Stevens Institute of Technology   (United States)

^c School of Dentistry   (South Korea)

Author keywords

ATTEMPTS; Heparin; Prodrug; Protamine; Targeted delivery; Tissue type plasminogen activator

Indexed keywords

CONJUGATION; DRUG DELIVERY SYSTEMS; ELECTROSTATIC BINDING; PLASMINOGENS;

ANTIBODIES; BIODEGRADATION; CHEMICAL BONDS; ELECTROSTATICS; ENZYMES; OXIDATION; TISSUE; TOXICITY;

DRUG DOSAGE;

3 (2 PYRIDYLDITHIO)PROPIONIC ACID N HYDROXYSUCCINIMIDE ESTER; ALTEPLASE; ARGININE DERIVATIVE; CARBOHYDRATE; CYSTEINE DERIVATIVE; FIBRIN ANTIBODY; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE DERIVATIVE; PLASMINOGEN; PROPIONIC ACID DERIVATIVE; PROTAMINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BINDING AFFINITY; BLOOD CLOT; CONFERENCE PAPER; CONJUGATION; CONTROLLED STUDY; CROSS LINKING; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TOXICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SYSTEMIC DISEASE; THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; FIBRINOLYSIS; PLASMIN; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 10044275517     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.07.020     Document Type: Conference Paper

References (28)

1. M. Vellard The enzyme as drug: application of enzymes as pharmaceuticals Curr. Opin. Biotechnol. 14 2003 444 450
2. V.P. Torchilin Drug targeting Eur. J. Pharm. Sci. 11 2000 S81 S91
3. P.A. Trail, D.H. King, and G.M. Dubowchik Monoclonal antibody drug immunoconjugates for targeted treatment of cancer Cancer Immunol. Immunother. 52 2003 328 337
4. P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, H. Ryan, W. Hallett, H.-R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D.A. Flowers, and I. Bernstein Gemtuzumab ozogamicin, a potent and selective anti-cd33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug. Chem. 13 2002 47 58
5. M.L. Linenberger, D.G. Maloney, and I.D. Bernstein Antibody-directed therapies for hematological malignancies Trends Mol. Med. 8 2 2002 69 76
6. C. Halin, V. Gafner, M.E. Villani, L. Borsi, A. Berndt, H. Kosmehl, L. Zardi, and D. Neri Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res. 63 2003 3202 3210
7. I. Niculescu-Duvaz, and C.J. Springer Antibody-directed enzyme prodrug therapy (ADEPT): a review Adv. Drug Deliv. Rev. 26 1997 151 172
8. K.D. Bagshawe Antibody-directed enzyme prodrug therapy Clin. Pharmacokinet. 27 5 1994 368 376
9. D. Collen, and H. Lijnen Fibrinolysis and the control of hemostasis G. Stamatoyannopoulos A.W. Nienhuis P.W. Majerus H. Varmus The Molecular Basis of Blood Diseases 1994 W.B. Saunders Philadelphia 725 752
10. E. Haber, T. Quertermous, G.R. Matsueda, and M.S. Runge Innovative approaches to plasminogen activator therapy Science 243 1989 51 56
11. J.I. Weitz, R.J. Stewart, and J.C. Fredenburgh Mechanism of action of plasminogen activators Thromb. Haemost. 82 1999 974 982
12. Y. Byun, and V.C. Yang A delivery system for targeted thrombolysis without risk of hemorrhage ASAIO J. 44 1998 638 641
13. J.-F. Liang, Y. Li, H. Song, Y.-J. Park, S.S. Naik, and V.C. Yang ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs J. Control. Release 78 2002 67 79
14. Y.-J. Park, J.-F. Liang, H. Song, Y. Li, S.S. Naik, and V.C. Yang ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects Adv. Drug Deliv. Rev. 55 2003 251 265
15. J.-F. Liang, Y. Li, and V.C. Yang A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro Int. J. Pharm. 202 2000 11 20
16. J.-F. Liang, Y. Li, M.E. Connell, and V.C. Yang Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug delivery system AAPS PharmSci. 2 1 2000
17. A. Lanevschi, J.W. Kramer, S.A. Greene, and K.M. Meyers Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs Am. J. Vet. Res. 57 1996 1124 1130
18. J. Edy, F. De Cock, and D. Collen Inhibition of plasmin by normal and antiplasmin-depleted human plasma Thromb. Res. 8 1976 513 518
19. C. Vermylen, R.A. De Vreker, and M. Verstraete A rapid enzymatic method for assay of fibrinogen: fibrin polymerization time (FPT Test) Clin. Chim. Acta 8 1963 418 424
20. L.J. Downing, R.M. Strieter, A.M. Kadell, C.A. Wilke, L.J. Greenfield, and T.W. Wakefield Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis J. Vasc. Surg. 28 1998 848 854
21. H.E. Conrad Heparin-Binding Proteins 1998 Academic Press San Diego, CA
22. D.L. Rabenstein Heparin and heparan sulfate: structure and function Nat. Prod. Rep. 19 2002 312 331
23. J.H. Yun, I.S. Han, L.-C. Chang, N. Ramamurthy, M.E. Meyerhoff, and V.C. Yang Electrochemical sensors for polyionic macromolecules: development and applications in pharmaceutical research PSST 2 1999 102 110
24. G. Montrucchio, E. Lupia, A. De Martino, L. Silvestro, S. Rizea Savu, G. Cacace, P.G. De Filippi, G. Emanuelli, and G. Camussi Plasmin promotes an endothelium-dependent adhesion of neutrophils Circulation 93 1996 2152 2160
25. H.K. Gold, J.T. Fallon, Y. Tsunehiro, R.C. Leinbach, B.A. Khaw, J.B. Newell, J.L. Guerrero, F.M. Vislosky, C.F. Hoyng, E. Grossbard, and D. Collen Coronary thrombolysis with recombinant human tissue-type plasminogen activator Circulation 70 1984 700 707
26. D. Collen, J.M. Stassen, and M. Verstraete Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis J. Clin. Invest. 71 1983 368 376
27. J.-P. Clozel, P. Holvoet, and T. Tschopp Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs J. Card. Pharm. 12 1988 520 525
28. P.M. Farrehi, C.K. Ozaki, P. Carmeliet, and W.P. Fay Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice Circulation 97 1998 1002 1008